To understand your patient’s risk and minimize uncertain results, you need a genetic test designed specifically for patients with a high risk personal and/or family breast cancer history. BRCAplus tests critical breast cancer genes with published guidelines for medical management, so you can help your patient make confident, personalized screening and prevention decisions.
When finding the answer is critical for guiding your patient’s healthcare, CancerNext is a comprehensive 34-gene panel that identifies inherited risks for at least 8 types of cancers, giving you more information to make better treatment and management decisions.
For patients with a complex personal or family history of cancer, CustomNext gives you the flexibility to choose which genes to analyze so you can accurately diagnose, treat, and manage your patient’s cancer risks.
Understanding high-risk breast cancer patients such as those with early-onset or multiple diagnoses of breast cancer, male breast cancer, and/or with a family history of disease is made clearer with BreastNext, a 17-gene panel, offering more precision to identify and manage hereditary breast cancer.
Every patient diagnosed with epithelial ovarian cancer meets criteria for hereditary cancer genetic testing. OvaNext, a 25-gene panel, offers the most comprehensive testing for gynecologic cancers to increase the chance of identifying and managing hereditary cancer risks.
Since hereditary prostate cancer is not well understood or often recognized, clinicians need clear results to guide treatment decisions. ProstateNext is a 14-gene panel which offers more precision to identify and manage hereditary prostate cancer.
Patients with a suspicious personal or family history of colorectal cancer or polyps benefit from early detection and cancer prevention. Identify patients with an increased risk by using ColoNext, a 17-gene panel designed to provide more precise data to help guide personalized medical management recommendations such as earlier or more frequent colonoscopies.
TumorNext-HRD clearly determines patients who may benefit from treatment with PARP inhibitors in one simple test. It simultaneously understands hereditary risk as it detects and differentiates between germline and somatic mutations in homologous recombination repair genes including BRCA1 and BRCA2.
When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy, you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment decisions.
For inquiries & concerns, email us at [email protected]